Compare ROAD & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROAD | COGT |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.5B |
| IPO Year | 2018 | 2018 |
| Metric | ROAD | COGT |
|---|---|---|
| Price | $116.28 | $34.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $123.50 | $30.17 |
| AVG Volume (30 Days) | 483.4K | ★ 2.5M |
| Earning Date | 02-05-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.46 | N/A |
| EPS | ★ 1.84 | N/A |
| Revenue | ★ $2,812,356,000.00 | N/A |
| Revenue This Year | $25.23 | N/A |
| Revenue Next Year | $10.22 | N/A |
| P/E Ratio | $62.52 | ★ N/A |
| Revenue Growth | ★ 54.20 | N/A |
| 52 Week Low | $64.79 | $3.72 |
| 52 Week High | $138.90 | $43.73 |
| Indicator | ROAD | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 59.87 | 43.79 |
| Support Level | $106.61 | $32.93 |
| Resistance Level | $116.21 | $36.88 |
| Average True Range (ATR) | 4.29 | 1.62 |
| MACD | 0.46 | -0.72 |
| Stochastic Oscillator | 88.15 | 24.28 |
Construction Partners Inc operates as a civil infrastructure company. It specializes in the construction and maintenance of roadways. The company through its subsidiaries, provides various products and services to both public and private infrastructure projects, with an emphasis on highways, roads, bridges, airports, and commercial and residential developments. Its operations consist of manufacturing and distributing hot mix asphalt, paving activities, including the construction of roadway base layers and application of asphalt pavement, site development, including the installation of utility and drainage systems, and others. The company has a single segment which predominantly consists of infrastructure and road construction, and operates across various states in the United States.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.